Andrew J. Cutler, MD

Treatment Patterns Among MDD Patients During Major Depressive Episodes

BACKGROUND: Many MDD patients fail to achieve remission. Current literature focuses on one major depressive episode (MDE); treatment over multiple MDEs has not been extensively explored. ...

Sara Higa , PharmD, MS;

Rakesh Jain , MD, MPH, RD;

Machaon Bonafede , PhD, MPH;

Patrick Gillard , PharmD, MS;

Katelyn Keyloun , PharmD, MS;

Julie Park , BA, MPH;

Amy Tung , PharmD, MS;

Andrew J. Cutler , MD;

11/22/2019

Key Characteristics of the Long-Acting Injectable Atypical Antipsychotic Aripiprazole Lauroxil for the Treatment of Adults with Schizophrenia

Aripiprazole lauroxil and its 1-day initiation formulation were specifically developed using an innovative prodrug technology to provide long-acting injectable formulations of aripiprazol...

Andrew J. Cutler , MD;

10/26/2023

Efficacy and Safety of a Delayed-Release and Extended-Release Methylphenidate Formulation in Children With ADHD: Results From a Pivotal Phase 3 Trial in a Naturalistic Setting

Purpose: Evening-dosed HLD200 is a delayed-release and extended-release methylphenidate (DR/ER-MPH) designed to provide treatment effect in the early morning, throughout the day, and into...

Steven Pliszka , MD;

Jeffrey Newcorn , MD;

Samantha Bostrom , MD;

Frank López , MD;

Andrea Marraffino , PhD;

Norberto DeSousa , MA;

Bev Incledon , PhD;

F. Randy Sallee , MD, PhD;

Andrew J. Cutler , MD;

Valerie Arnold , MD;

Timothy Wilens , MD;

11/22/2019

Qelbree® (viloxazine extended-release capsules): Final Results of the Long-Term, Phase 3, Open-Label Extension Trial in Adults With Attention-Deficit/Hyperactivity Disorder

Final results of a long-term, open-label extension of a pivotal phase 3 study leading to FDA-approval of viloxazine extended-release capsules (Qelbree®) in adults.

Andrew J. Cutler , MD;

10/26/2023

Clinical Evaluation of Abuse Potential of Buprenorphine /Samidorphan (BUP/SAM) Combination

Introduction: Buprenorphine (BUP)/samidorphan (SAM) combination is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder (MDD). The human abu...

Narinder Nangia , PhD;

Arielle Stanford , MD;

Andrew J. Cutler , MD;

Sanjeev Pathak , MD;

Sanjay Mathew , MD;

Michael E. DeBakey ;

Beatrice Setnik , PhD;

03/01/2019

Real-World Effectiveness of Deutetrabenazine When Initiated Using a 4-Week Patient Titration Kit: Interim Results of the START Study

START is an ongoing, noninterventional, prospective, single-arm, 2-cohort (tardive dyskinesia [TD] and Huntington disease) study evaluating the effectiveness of deutetrabenazine initiated...

Andrew J. Cutler , MD;

10/26/2023

Background: The impact of possible tardive dyskinesia (TD) was assessed in RE KINECT, a real-world study of antipsychotic-treated outpatients. Based on clinician assessments, patients wer...

William Lenderking , PhD;

Michael Serbin , PharmD;

Chuck Younan , PharmD;

Ericha Franey , PhD;

Andrew J. Cutler , MD;

Stanley Caroff , MD;

11/22/2019